Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Should sarcoidosis patients stay on infliximab? new trial aims to find out

NCT ID NCT05689879

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial looks at whether people with severe sarcoidosis who are in remission should stop or continue taking infliximab. 32 adults who have been on infliximab for at least 6 months and are stable on low-dose steroids will be randomly assigned to stop or continue the drug. The goal is to see which strategy better prevents major relapses over the next year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
infliximab (a TNF-alpha inhibitor)
What this could lead to
If successful, this could show that continuing infliximab longer helps prevent relapses in people with severe sarcoidosis.
What could go wrong
This is a small, early-stage trial with only 32 participants, so results may not apply to everyone. There is also a risk of side effects from continued infliximab use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

32 people

The number who actually took part.

Started

Mar 2023

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age superior or equal to 18 years * Clinical and radiological presentation consistent with sarcoidosis * Presence of non-caseating granulomas in at least one organ * Exclusion or other causes of granulomas * Infliximab treatment for at least 6 months * Steroid dosage \< or equal to 10 mg/day for at least 6 months * No activity of the disease (ePOST score 0) for at least 6 months * Normal ACE (angiotensin converting enzyme) and serum calcemia level * Signed informed consent * Affiliated to the National French social security system * As infliximab is the most used TNF-alpha antagonists, we decided to include only patients treated with infliximab to increase the homogeneity. Exclusion Criteria: * Pregnancy or breast-feeding * Positive IGRA (Interferon Gamma Release Assays) test without previous antituberculous antibiotherapy * Active infection * Patients with moderate to severe heart failure (NYHA class III/ IV) * Severe liver function disorders * Alcoholism * Severe kidney function disorders * Pre-existing blood dyscrasias * History of cancer in the 5 years before enrolment (except for cutaneous non melanoma cancers) * Concurrent vaccination with live vaccines during therapy * Inability to understand information about protocol * Adult subject under legal protection or unable ton consent * Absence of effective contraceptive method for men and women for duration of the study and 6 months after the end of participation * Concomitant participation to another biomedical research (only Category 1 trial according to the french law)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcoidosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

sarcoidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcoidosis

Contacts and locations

Locations

  • Hôpital de la Pitié-Salpêtrière

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.